Internal Server Error

MedGenome - About the company

MedGenome is a series E company based in Bengaluru (India), founded in 2013 by Sreedhar Santhosh and Mahesh Pratapneni. It operates as a Provider of DNA sequencing, bioinformatics, and multiomics services. MedGenome has raised $264M in funding from investors like Peak XV Partners, Novo Holdings and HDFC, with a current valuation of $*****. The company has 81 active competitors, including 6 funded and 6 that have exited. Its top competitors include companies like Metropolis India, CORE and Lilac Insights.

Company Details

Provider of DNA sequencing, bioinformatics, and multiomics services. It offers a comprehensive suite of genomic services which include whole genome and exome sequencing, single-cell sequencing, spatial transcriptomics, and immune profiling. It also provides robust bioinformatics support, including analysis pipelines and data visualization tools, to facilitate research and drug discovery. The services are tailored to support research in various areas, including rare disease research, cancer research, and antibody discovery.
Social
XFacebook
Part Of
Registered Address
Sy. Nos. 94/1C and 94/2, Tower 1, Ground Floor, Veerasandra Village, Attibele Hobli, Electronic City Phase-1, Electronics City, Bangalore, Bangalore South, Karnataka, India, 560100
Key Metrics
Founded Year
2013
Location
Bengaluru, India
Stage
Series E
Total Funding
$264M in 10 rounds
Latest Funding Round
Post Money Valuation
$***** as on Dec 18, 2021
Ranked
Annual Revenue
₹100 - ₹500 Cr as on Mar 31, 2025
Employee Count
922 as on May 31, 2025
Investment & Acquisitions
Similar Companies
Sign up to download MedGenome's company profile

MedGenome's funding and investors

MedGenome has raised a total funding of $264M over 10 rounds. Its first funding round was on Aug 20, 2013. Its latest funding round was a Series E round on Jul 21, 2025 for $*****. 3 investors participated in its latest round. MedGenome has 21 institutional investors and 11 angel investors.

Here is the list of recent funding rounds of MedGenome:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jul 21, 2025
6150887
Series E
7478122
1813979
8293806
8746817
Aug 30, 2022
9811837
Series D
7726661
9211738
3442365
Jul 15, 2021
3636971
Series D
2587761
4411619
lockAccess funding benchmarks and valuations. Sign up today!

MedGenome's founders and board of directors

Founder? Claim Profile
The founders of MedGenome are Sreedhar Santhosh and Mahesh Pratapneni. Mahesh Pratapneni, Felix Olale and Vedam Ramprasad are the CEOs of MedGenome.
Here are the details of MedGenome's key team members:

MedGenome's Board of Directors

MedGenome's board has 4 active members. Mahesh Pratapneni is part of team and Navjeewan Jatinder Khosla, Prasad Bhagwan Shejale and Shankar Mahadevappa Prasad are independent board members.
Here is the list of MedGenome's board of directors:
Name
Type
Representing
Status
Duration
Team
-
Current
7y 1m
Independent board member
-
Current
2y 0m
viaiyua
Independent board member
-
Current
9y 7m
bcudemv
Independent board member
-
Current
4y 2m

MedGenome's employee count trend

MedGenome has 922 employees as of May 25. The total employee count is 5.0% more than what it was in May 24. Here is MedGenome's employee count trend over the years:
Employee count trend for MedGenome
lockUncover MedGenome's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

MedGenome's Competitors and alternates

Top competitors of MedGenome include Metropolis India, CORE and Lilac Insights. Here is the list of Top 10 competitors of MedGenome, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for MedGenome
MedGenome
2013, Bengaluru (India), Series E
Provider of DNA sequencing, bioinformatics, and multiomics services
$264M
70/100
2nd
Logo for Metropolis India
Metropolis India
1981, Mumbai (India), Public
Chain of diagnostic centers
$11.7M
69/100
3rd
Logo for CORE
CORE
2012, Gurugram (India), Acquired
Laboratory offering biomarker analysis
$17.3M
52/100
4th
Logo for Lilac Insights
Lilac Insights
2011, Mumbai (India), Series A
Provider of genetic diagnostic advisory services for infant
$11M
52/100
5th
Logo for Sterling Accuris Diagnostics
Sterling Accuris Diagnostics
2015, Ahmedabad (India), Series C
Chain of pathology labs
$41.7M
51/100
6th
Logo for Dr Dangs Lab
Dr Dangs Lab
1983, Delhi (India), Unfunded
Provider of diagnostic testing services in various medical specialties
-
-
50/100
7th
Logo for CRL Diagnostics
CRL Diagnostics
2015, Delhi (India), Unfunded
Chain of pathology laboratory services
-
-
49/100
8th
Logo for OncoStem
OncoStem
2011, Bengaluru (India), Series A
Developer of prognostic tests for the detection of cancer
$9M
45/100
9th
Logo for Rivaara Labs
Rivaara Labs
2019, Mumbai (India), Series A
Provider of molecular diagnostic test lab
$9.89M
43/100
10th
Logo for Accuprobe Diagnostics
Accuprobe Diagnostics
2015, Delhi (India), Funding Raised
Provider of pathology testing services at home
-
39/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on MedGenome's competitors? Click here to see the top ones

Financials of MedGenomeFY 25 Available

MEDGENOME LABS LIMITED, the legal entity associated with MedGenome, generated between ₹100 Cr and ₹500 Cr in revenue for the financial year ending on Mar 31, 2025. The revenue of MEDGENOME LABS LIMITED has a compounded annual growth rate (CAGR) of 36% in the last 1 year.

Financial Statement Summary

Metrics
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
Income Statement
Revenue
9849
6385
6995
8350
9776
Total Sales
1166
9018
3976
9277
7554
Total Expenses
6533
2561
9901
3970
4609
Operating Expenses
4530
6333
6926
8224
5917
Employee Expenses
3093
5721
2667
2259
6005
Marketing Expenses
1839
2343
9150
6113
3915
Operating Income (EBIT)
4617
2676
1045
1273
6653
Interest Expenses
6437
5834
3726
2452
5793
Expenses from other activities
9652
1569
2461
5218
2691
EBITDA
8682
1138
8787
2865
2246
Taxes
4846
3307
9379
4139
8865
Net Profit
8746
6016
1147
5190
7796
Balance Sheet
Assets
7164
3961
6542
7176
9476
Cash Equivalent
5100
9456
7332
9185
4562
Accounts Receivables
3197
3031
6786
8004
2992
Inventory
5588
8709
7700
4171
4864
Liabilities
2940
8654
6522
9238
3174
Total Debt
3094
9373
5598
2447
9929
Accounts Payable
3330
6266
7692
1805
6597
Equities
7281
6173
8756
6799
9143
Cashflow Statement
Cash from Operating activities
6642
7835
4728
1665
5552
Cash from Investing activities
9786
6186
9500
4772
6005
Net cash from Financing activities
9071
6249
9656
5391
7762

Detailed Financials (Income Statement, Balance Sheet, Cashflow Statement)

Gain deeper financial insights
of this entity
$10.99$2.53(excl. taxes)
Download Sample Report
What documents will you get?
  • Financial Summary & Charts
  • Detailed Income Statement, Balance Sheet, Cashflow Statement
  • Profitability Ratios, Liquidity Ratios, Growth Rates

MedGenome's Investments and acquisitions

MedGenome has not made any investments yet. MedGenome has made 6 acquisitions.
Here is the list of latest three $acquisitions:lockFilter this list
Date of Investment/Acquisition
Type
Company Name
Founded Year
Location
May 18, 2026
Acquisition
-
Mar 02, 2026
Acquisition
2006
Navi Mumbai (India)
Nov 04, 2025
Acquisition
-
lockWant to know more about where corporates are investing? Sign up today!
See all acquisitions by MedGenome

Reports related to MedGenome

Here is the latest report on MedGenome's sector:

News related to MedGenome

lockFilter this list
Media has covered MedGenome for a total of 6 events in the last 1 year, 2 of them have been about company updates.
•
•
•
ITM Appoints Dr. Celine Wilke as Chief Medical OfficerGlobeNewswire•Apr 01, 2025•ITM, MedGenome
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about MedGenome

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford